Literature DB >> 15936463

The relationship between insulin resistance assessed by HOMA-IR and serum osteoprotegerin levels in obesity.

Betul Ugur-Altun1, Armagan Altun, Murat Gerenli, Armagan Tugrul.   

Abstract

AIM: We investigated the relationship between insulin resistance and serum osteoprotegerin (OPG) levels in healthy obese subjects and healthy lean controls.
METHODS: Fifty obese subjects (age: 31+/-8 years) and 24 lean controls (age: 30+/-7 years) were included in the study. We used the homeostasis model assessment for insulin resistance (HOMA-IR) index as the index of insulin resistance. OPG levels were measured with the commercial ELISA kit. Obese subjects were studied in three groups: Group I (n = 25) HOMA-IR index < 2.24, Group II (n = 13) index 2.24-3.59, Group III (n = 12) index > 3.59. Group IV (n = 24) was the lean controls with HOMA-IR index < 2.24.
RESULTS: Obese subjects with increased insulin resistance (Group III) had lower OPG values than other groups (11.88+/-7.43 pg/ml, 16.39+/-6.39 pg/ml, 17.37+/-9.61 pg/ml, and 18.1+/-6.65 pg/ml, respectively; Group I versus Group III p = 0.036; Group III versus Group IV p = 0.012). We also found significant inverse correlations between OPGc (corrected for BMI) and fasting glucose (r = -0.325, p = 0.005), fasting insulin (r = -0.404, p = 0.0001) as well as HOMA-IR (r = -0.428, p = 0.0001). Increased fibrinogen level was found in Group III than Group IV (9.32+/-1.97 micromol/l versus 7.47+/-1.65 micromol/l, respectively; p = 0.005). In conclusion, insulin resistance in obesity is associated with decreased serum OPG levels and increased fibrinogen levels. The relationship between serum OPG levels and HOMA-IR may provide an insight into vascular endothelial dysfunction in obesity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15936463     DOI: 10.1016/j.diabres.2004.10.011

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  12 in total

1.  Physical functioning related to C-reactive protein and fibrinogen levels in mid-life women.

Authors:  Kristin Tomey; MaryFran Sowers; Huiyong Zheng; Elizabeth A Jackson
Journal:  Exp Gerontol       Date:  2009-10-09       Impact factor: 4.032

Review 2.  Osteoprotegerin in Cardiometabolic Disorders.

Authors:  C Pérez de Ciriza; A Lawrie; N Varo
Journal:  Int J Endocrinol       Date:  2015-05-11       Impact factor: 3.257

3.  Association of Osteoprotegerin with Obesity, Insulin Resistance and Non-Alcoholic Fatty Liver Disease in Children.

Authors:  Meltem Erol; Ozlem Bostan Gayret; Hikmet Tekin Nacaroglu; Ozgul Yigit; Oguzhan Zengi; Mehmet Salih Akkurt; Mehmet Tasdemir
Journal:  Iran Red Crescent Med J       Date:  2016-11-01       Impact factor: 0.611

4.  The Association of Inflammatory Markers With Nonalcoholic Fatty Liver Disease Differs by Human Immunodeficiency Virus Serostatus.

Authors:  Jennifer C Price; Ruibin Wang; Eric C Seaberg; Matthew J Budoff; Lawrence A Kingsley; Frank J Palella; Mallory D Witt; Wendy S Post; Chloe L Thio
Journal:  Open Forum Infect Dis       Date:  2017-07-23       Impact factor: 3.835

5.  Serum Osteoprotegerin Is a Potential Biomarker of Insulin Resistance in Chinese Postmenopausal Women with Prediabetes and Type 2 Diabetes.

Authors:  Peng Duan; Min Yang; Meilin Wei; Jia Liu; Ping Tu
Journal:  Int J Endocrinol       Date:  2017-01-31       Impact factor: 3.257

Review 6.  Role of osteoprotegerin/receptor activator of nuclear factor kappa B/receptor activator of nuclear factor kappa B ligand axis in nonalcoholic fatty liver disease.

Authors:  Lucia Pacifico; Gian Marco Andreoli; Miriam D'Avanzo; Delia De Mitri; Pasquale Pierimarchi
Journal:  World J Gastroenterol       Date:  2018-05-21       Impact factor: 5.742

Review 7.  The Role of Osteoprotegerin as a Cardioprotective Versus Reactive Inflammatory Marker: the Chicken or the Egg Paradox

Authors:  Flora Özkalaycı; Öykü Gülmez; Betül Uğur-Altun; Seithikurippu Ratnas Pandi-Perumal; Armağan Altun
Journal:  Balkan Med J       Date:  2018-04-24       Impact factor: 2.021

8.  Effects of Sweet Cherry Polyphenols on Enhanced Osteoclastogenesis Associated With Childhood Obesity.

Authors:  Filomena Corbo; Giacomina Brunetti; Pasquale Crupi; Sara Bortolotti; Giuseppina Storlino; Laura Piacente; Alessia Carocci; Alessia Catalano; Gualtiero Milani; Graziana Colaianni; Silvia Colucci; Maria Grano; Carlo Franchini; Maria Lisa Clodoveo; Gabriele D'Amato; Maria Felicia Faienza
Journal:  Front Immunol       Date:  2019-05-03       Impact factor: 7.561

9.  Inverse Regulation of Serum Osteoprotegerin and B-Type Natriuretic Peptide Concentrations by Free Fatty Acids Elevation in Young Healthy Humans.

Authors:  Marta Dobrzycka; Adrian Kołakowski; Magdalena Stefanowicz; Natalia Matulewicz; Agnieszka Nikołajuk; Monika Karczewska-Kupczewska
Journal:  Nutrients       Date:  2022-02-17       Impact factor: 5.717

10.  Aortic flow propagation velocity, epicardial fat thickness, and osteoprotegerin level to predict subclinical atherosclerosis in patients with nonalcoholic fatty liver disease.

Authors:  Didem Oğuz; Hakan Ümit Ünal; Hacer Eroğlu; Öykü Gülmez; Halime Çevik; Armağan Altun
Journal:  Anatol J Cardiol       Date:  2016-03-28       Impact factor: 1.596

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.